Clinical trial

Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in…

NCT00277472 · Novartis, Industry · Completed

Key facts

NCT number NCT00277472
Title Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension
Official title A 28-week, Multicenter Study to Evaluate the Effects of Valsartan/Hydrochlorothiazide (160/12.5 mg) in Comparison With Hydrochlorothiazide (25 mg) Monotherapy, for the Treatment of Patients With Hypertension, Uncontrolled by Hydrochlorothiazide (12.5 mg) Monotherapy
Lead sponsor Novartis, Industry
Status Completed
Phase Phase 4
Study type Interventional
Conditions Hypertension
Intervention type Drug
Interventions Valsartan/Hydrochlorothiazide, HCTZ
Enrollment 300
Start date Nov 1, 2005
Primary completion Nov 1, 2005
First posted Jan 16, 2006
Last update posted Jun 7, 2011
Countries United States

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies